K Pharma, Inc.

Business Details

The company operates a hybrid model targeting intractable neurological diseases, combining an iPS drug discovery business (6 pipelines) and a regenerative medicine business (5 pipelines) utilizing iPS cells. Based on industry-academia collaboration with Keio University School of Medicine and others, the company is advancing research and development in areas of unmet medical need such as ALS, spinal cord injury, and hearing loss. Revenue is expected to come from license contract upfront payments, milestones, and royalties, but the company continued to record zero revenue and an ongoing operating loss during the current quarter.

Recent Overview

Losses widened due to increased R&D expenses, while clinical trial preparations progressed for the spinal cord injury and cerebral infarction pipelines

In the first quarter of FY2026 (ending December 2026) (January to March), revenue remained at zero. R&D expenses increased to ¥103 million (from ¥82 million in the same quarter of the prior year), and the operating loss widened to ¥237 million (from ¥199 million in the same quarter of the prior year). Due to the recording of ¥7 million in bond interest and ¥7 million in impairment loss as an extraordinary loss, the net loss for the quarter came to ¥250 million. Meanwhile, there was a series of pipeline advancements, including the conclusion of a basic manufacturing outsourcing agreement with Nikon Cell Innovation for the subacute spinal cord injury pipeline, the extension of the joint research agreement on chronic cerebral infarction through March 2029, and the receipt of a notice of allowance for the ALS patent in the United States. There is no change to the full-year earnings forecast (operating loss of ¥1,520 million, net loss of ¥1,616 million).

Key Products

Growth Drivers

• Progress in preparations for the Phase III trial (confirmatory clinical trial) of the ALS drug together with Alfresa Pharma Corporation
• Strengthening of the intellectual property foundation through receipt of a notice of allowance for the ALS drug patent in the United States
• Conclusion of a basic manufacturing outsourcing agreement with Nikon Cell Innovation Co., Ltd. for a company-sponsored clinical trial targeting subacute spinal cord injury
• Concretization of preparations for a company-sponsored clinical trial through the extension of the joint research agreement on chronic cerebral infarction with the National Hospital Organization Osaka Medical Center (through March 2029)
• Continued acquisition of nonclinical data through the extension of the joint research agreement on hearing loss disease with Kitasato Institute (through March 2027)
• Securing of R&D funding through the issuance of unsecured convertible bonds with stock acquisition rights (¥1,500 million)
• Securing of liquidity on hand through cash and deposits of ¥2,708 million to continue research activities for the time being

Risks

• Zero revenue has continued and operating cash flow has been persistently negative, giving rise to events that raise substantial doubt about the company's ability to continue as a going concern (although at present it is judged that no material uncertainty exists)
• For the full year of FY2026 (ending December 2026), an ordinary loss of ¥1,550 million and a net loss of ¥1,616 million are expected, with losses continuing to widen
• The equity ratio declined from 43.1% (end of FY2025 (ended December 2025)) to 36.0% (end of Q1 FY2026), and the accumulated deficit in retained earnings expanded (-¥1,243 million) due to the recorded net loss
• The fixed liability of ¥1,500 million in bonds continues, and the bond interest burden (¥7 million in the current quarter) contributes to increasing losses
• Risk of failure in clinical trials for the development pipeline, and uncertainty regarding discussions with regulatory authorities (such as the PMDA)
• The timing of realization of licensing-out and milestone income is uncertain, and additional fundraising at an appropriate time is not guaranteed
• Risk that the increasing trend in R&D expenses (up approximately 26% year on year) will accelerate the pace of decline in cash and deposits